# Systemic Avastin Therapy in Age-Related Macular Degeneration

> **NCT00531024** · PHASE2,PHASE3 · COMPLETED · sponsor: **The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery** · enrollment: 30 (estimated)

## Conditions studied

- Macular Degeneration

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Sodium Chloride

## Key facts

- **NCT ID:** NCT00531024
- **Lead sponsor:** The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2008-01
- **Final completion:** 2008-03
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2009-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00531024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00531024, "Systemic Avastin Therapy in Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00531024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*